Table 3.

Pathology results.

Pathology	N (%)
Malignancy	130 (59.6)
Non-small-cell lung cancer	47 (21.6)
Adenocarcinoma	42 (19.3)
Squamous	3 (1.4)
Large cell	2 (0.9)
Mesothelioma	20 (9.2)
Epithelioid	13 (6.0)
Sarcomatoid	3 (1.4)
Biphasic	4 (1.8)
Others	63 (28.9)
Small-cell lung cancer	2 (0.9)
Breast	27 (12.4)
Renal	2 (0.9)
Ovarian adenocarcinoma	7 (3.2)
Papillary serous	4 (1.8)
Melanoma	2 (0.9)
Colorectal	1 (0.5)
Chronic lymphocytic leukemia	4 (1.8)
Lymphoma/lymphoproliferative	2 (0.9)
Parotid	1 (0.5)
Sarcoma	2 (0.9)
Thyroid	1 (0.5)
Laryngeal	2 (0.9)
Esophageal	1 (0.5)
Vulvar	1 (0.5)
Carcinoma unknown primary	4 (1.8)
Nonspecific pleuritis	64 (29.4)
Reactive mesothelial changes	10 (4.6)
Atypical mesothelial changes	9 (4.1)
Granulomatous pleuritis	3 (1.4)
Eosinophilic pleuritis	1 (0.5)
Hematoma	1 (0.5)